ClinicalTrials.gg
CompletedNCT01442792X-PLORERUpdated Jun 23, 2022

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

A Phase 2 interventional study of UFH and Rivaroxaban (Xarelto, BAY59-7939) in Cardiovascular Disease and Coronary Artery Disease, sponsored by Bayer. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.

Primary conditionCoronary Artery DiseaseRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing rivaroxaban in Coronary Artery Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Coronary Artery Disease.

Enrollment
7th of 14
108 · median 104
Started
2011
the only one that year
Phase 2
Only one
of the 14
Registered
1st of 14
by date
Lead sponsor
2 of 14
Bayer

Among the 14 studies testing rivaroxaban in Coronary Artery Disease, this one is the 7th largest by enrollment, is the only one that started in 2011, is the only one in phase 2, and was the 1st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 14 studies testing rivaroxaban in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing rivaroxaban in Coronary Artery Disease, or all of them as a file.
02

Study summary

Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD). Although PCI is highly effective for the management of CAD, it can potentiate an existing prothrombotic state around lesion areas. A certain level of anticoagulation is required to perform planned PCI safely and to minimize the periprocedural risk of thrombosis and its attendant complications, including myocardial ischemia and infarction (heart attack). Many different anti-thrombotic regimens have been investigated and are currently in use. The aim of this study is to explore whether Rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy, can effectively suppress thrombosis and related adverse ischemic events, upon balloon inflation and stent expansion, during elective PCI, without increasing bleeding. The treatment assignment will be done in a semi-blinded design, eg, no blinding for randomization either to Rivaroxaban (one of the three arms) or the control (UFH) group. However, all will be blinded for the treatment dose of rivaroxaban (either 10mg or 20 mg).The 10 mg rivaroxaban plus 50 IU UFH arm will not be blinded.

03

Conditions studied

  • Cardiovascular Disease
  • Coronary Artery Disease

Browse trials for

Keywords

  • Angioplasty, Balloon, Coronary
04

In context

Coronary Artery Disease Reclassified

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's enrollment of 108 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol
  • Symptomatic coronary artery disease due to undergo an elective (non-emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s). Cardiac standard troponin at baseline is within the normal limits

Exclusion criteria

Exclusion Criteria:

  • Conditions that may increase the risk of the PCI procedure
  • Conditions that may increase the risk of bleeding
  • Significant valvular heart disease
  • Calculated ≤30 mL/min
  • Current use of anticoagulant drugs including Vitamin K antagonist (VKA), factor IIa or factor XA inhibitors
  • Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)
  • Chronic treatment with aspirin > 100mg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: UFH

  • Experimental
    Arm 2

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Arm 3

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Arm 4

    Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH

Interventions

  • DrugUFH

    Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds

  • 10 mg single dose Rivaroxaban (per os)

  • 20 mg single dose Rivaroxaban (per os)

  • DrugRivaroxaban (Xarelto, BAY59-7939) and UFH

    Drug page: Rivaroxaban

    10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)

07

What researchers measure

Primary outcomes

  1. The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event

    Time frame: During the index Percutaneous Coronary Intervention procedure

  2. The percentage of subjects who experience an angiographic flow limiting thrombotic event

    Time frame: During the index Percutaneous Coronary Intervention procedure

  3. The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment

    Time frame: During the index Percutaneous Coronary Intervention procedure

  4. The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure

    Time frame: During the index Percutaneous Coronary Intervention procedure

Secondary outcomes

  1. Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5)

    Time frame: Up to 30 days post index Percutaneous coronary intervention procedure

  2. Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization

    Time frame: Up to 30 days post index Percutaneous coronary intervention procedure

  3. Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  4. Coagulation profile of Rivaroxaban (Prothrombin time)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  5. Coagulation profile of Rivaroxaban (Thrombin Time)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  6. Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  7. Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  8. Coagulation profile of Rivaroxaban (Anti-Xa Activity)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  9. Coagulation profile of Rivaroxaban (endogenous thrombin potential)

    Time frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)

  10. Plasma concentration of Rivaroxaban

    Time frame: The day of percutaneous coronary intervention (PCI) (from 2 to 4 hours before to 6-8 hours after PCI)

08

Study locations

7 sites
  • Hasselt, 3500, Belgium
  • Liege, 4000, Belgium
  • Roeselare, 8800, Belgium
  • Amsterdam, 1091 AC, Netherlands
  • Amsterdam, 1105 AZ, Netherlands
  • Eindhoven, 5623 EJ, Netherlands
  • Zwolle, 8011 JW, Netherlands
09

References and documents

Publications

  • Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, de Winter RJ, van T Hof AW, Backx B, Lindeboom W, Kim SY, Kirsch B, van Eickels M, Misselwitz F, Verheugt FW. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost. 2015 Aug;114(2):258-67. doi: 10.1160/TH15-01-0061. Epub 2015 Apr 30. PubMed 25925992 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Jan 2013, 15 months.

Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 15 months is close to that.

Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Sep 29, 2011
StartActual
Oct 12, 2011
Primary completionActual
Jan 29, 2013
CompletionActual
Mar 4, 2013
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01442792
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 29, 2011
Start date
Oct 12, 2011
Primary completion
Jan 29, 2013
Completion
Mar 4, 2013
Last update
Jun 23, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion